Barclays Initiates Coverage On Forte Biosciences with Overweight Rating, Announces Price Target of $74

Benzinga · 2d ago
Barclays analyst Etzer Darout initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Overweight rating and announces Price Target of $74.